Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

Summary

This randomized clinical trial studies how well non-invasive ventilation works in reducing the need for intubation, or placement of a tube in the windpipe, in patients with cancer and respiratory failure. Respiratory failure is a condition in which not enough oxygen passes from the lungs to the blood, and is a common cause of admission to the emergency room in patients with hematological and solid tumor patients. Non-invasive positive pressure ventilation (NIPPV) is a method of delivering oxygen using a mask. It is not yet known whether NIPPV is better at improving the amount of oxygen in the blood, reducing shortness of breath, and the need for intubation than standard high flow oxygen (a tube with 2 prongs placed in the nostrils) in patients with cancer and respiratory failure.

Eligibility

Inclusion Criteria:

* Partial pressure of arterial oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio =\< 300 mmHg OR a peripheral capillary oxygen saturation (SaO2):FiO2 =\< 357
* Have a diagnosed malignancy
* Chest radiograph or computed tomography (CT) scan within =\< 3 months prior to study enrollment rules out primary or metastatic malignancy in the lungs or pleural space as a significant cause of respiratory insufficiency
* Probability of survival is at least 6 months

Exclusion Criteria:

* Presence of do not resuscitate (DNR)/do not intubate (DNI) orders at study entry
* Clinical evidence of left heart failure as the main etiology for respiratory compromise
* Evidence of active intrathoracic malignancy (primary or metastatic) in the lungs or pleural space that is a significant cause of respiratory insufficiency
* Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
* Evidence of accessory respiratory muscle use with breathing
* Shock (need for vasopressor therapy or mean arterial pressure \[MAP\] \< 60 despite fluid administration)
* Oliguric acute renal failure (urine output \< 500 ml/day) unless already on hemodialysis
* Patient already on NIPPV at the time of screening
* pH \< 7.30 or partial pressure of carbon dioxide (pCO2) \> 50 (if available)
* Fixed upper airway obstruction
* Airway or facial trauma that would hinder the use of a NIPPV mask
* Uncontrolled tachy or bradyarrhythmia or active myocardial ischemia defined as either: atrial fibrillation with rapid ventricular response (heart rate \[HR\] \> 120 beats per minute \[bpm\]), ventricular tachycardia or nonsustained ventricular tachycardia (any rate), supraventricular tachycardia (any rate), third degree heart block (any rate), heart rate less than 40 beats per minute (regardless of the rhythm)
* Active myocardial ischemia defined as a clinical presentation at the time of screening consistent with acute coronary syndrome which includes unstable angina and electrocardiogram (EKG) changes suggestive of an either an acute ST elevation myocardial infarction (new ST elevations or new left bundle branch block) or acute non-ST elevation myocardial infarction (new ST depressions, new T wave inversions)
* Glasgow Coma Scale (GCS) \< 8 or inadequate airway protective reflexes
* Undrained pneumothorax/pneumomediastinum
* Copious secretions (\> 20 cc's of sputum production per hour or significant hemoptysis defined as \> 100 cc's of hemoptysis in a 24 hour period
* Risk for gastric aspiration (ie; ileus, esophageal or bowel obstruction, active vomiting)
* Recent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)
* Inability to cooperate with NIPPV
* Refusal to receive NIPPV
* Respiratory arrest

Conditions3

Interventions1

Locations1 site

Find trials near these locations

Related trials

• A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors — BeOne Medicines
• Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) — Beijing Tongren Hospital
• Effect of Methylprednisolone on Systemic Inflammatory Response During Pediatric Congenital Open-Heart Surgery — Aga Khan University
• Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma — Sun Yat-sen University
• Glucocorticoids for Acute Drug Induced Liver Injury With Hyperbilirubinemia — General Hospital of Shenyang Military Region
• Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia — National Cancer Institute (NCI)
• A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) — Merck Sharp & Dohme LLC
• A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients — Oncotherapeutics

Browse More Trials